A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM).

MLA

Ades, Lionel, et al. “A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacytidine in Intermediate-2 and High-Risk Patients with Myelodysplastic Syndromes: A Study by the Groupe Francophone Des Myelodysplasies (GFM).” Haematologica, vol. 104, no. 4, Apr. 2019, pp. e131–33. EBSCOhost, https://doi.org/10.3324/haematol.2018.203885.

APA

Ades, L., Guerci-Bresler, A., Cony-Makhoul, P., Legros, L., Sebert, M., Braun, T., Delaunay, J., Desseaux, K., Chevret, S., & Fenaux, P. (2019). A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM). Haematologica, 104(4), e131–e133. https://doi.org/10.3324/haematol.2018.203885

Chicago

Ades, Lionel, Agnès Guerci-Bresler, Pascale Cony-Makhoul, Laurence Legros, Marie Sebert, Thorsten Braun, Jacques Delaunay, Kristell Desseaux, Sylvie Chevret, and Pierre Fenaux. 2019. “A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacytidine in Intermediate-2 and High-Risk Patients with Myelodysplastic Syndromes: A Study by the Groupe Francophone Des Myelodysplasies (GFM).” Haematologica 104 (4): e131–33. doi:10.3324/haematol.2018.203885.